| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 55,952 | 36,748 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 4,051 | 4,009 |
| Net decrease in cash, cash equivalents, and restricted cash | -12,890 | -3,574 |
| Cash and cash equivalents at beginning of period | 43,418 | - |
| Cash and cash equivalents at end of period | 30,528 | - |
SANGAMO THERAPEUTICS, INC (SGMO)
SANGAMO THERAPEUTICS, INC (SGMO)